نتایج جستجو برای: her2 receptors

تعداد نتایج: 236775  

Journal: :International journal of molecular medicine 2007
Marc-André Fortin Anna Orlova Per-Uno Malmström Vladimir Tolmachev

The direct instillation of radiolabelled conjugates in the urinary bladder is a promising path for the treatment of bladder carcinoma. The targeting of HER2/neu receptors expressed on the surface of many bladder carcinoma cells shows potential to be developed as a therapeutic strategy, and patients identified with a high risk of progression may benefit from adjuvant targeted radionuclide therap...

2017
Sonja Thaler Marcus Schmidt Sven Roβwag Gitta Thiede Arno Schad Jonathan P Sleeman

Amplification and/or overexpression of the human epidermal growth factor 2 (HER2) oncogene occurs in about 13-15% of invasive breast cancer and triggers breast cancer cell proliferation, survival and metastatic progression. Around half of all breast cancers with HER2 overexpression co-express hormone receptors (HR) such as those for estrogen and progesterone. Aberrant signaling through HER2 and...

Journal: :Circulation 2000
A M Feldman B H Lorell S E Reis

Trastuzumab, a monoclonal antibody against the HER2 receptor, was recently approved for the treatment of metastatic breast cancer. However, 28% of patients receiving both an anthracycline and trastuzumab developed heart failure. Although HER2 overexpression has been associated with the development of cancer, HER2 receptors seem to be cardioprotective because they mediate the activation of impor...

2017
Narjara González Suárez Gretchen Bergado Báez Mabel Cruz Rodríguez Amelia Gutiérrez Pérez Lisset Chao García Diana Rosa Hernández Fernández Judith Raymond Pous Belinda Sánchez Ramírez

The human epidermal growth factor receptor (HER1) and its partner HER2 are extensively described oncogenes and validated targets for cancer therapy. However, the effectiveness of monospecific therapies targeting these receptors is hampered by resistance emergence, which is frequently associated with the upregulation of other members of HER family. Combined therapies using monoclonal antibodies ...

2014
Antonio Ieni Valeria Barresi Rosario Caltabiano Anna Maria Cascone Rachele Del Sordo Daniela Cabibi Pio Zeppa Salvatore Lanzafame Angelo Sidoni Vito Franco Giovanni Tuccari

BACKGROUND Human epidermal growth factor receptor 2 (HER2) is considered to be a therapeutic and prognostic marker in the management of breast carcinoma (BC), although discordance rates between primary and metastatic or locally recurrent lesions have been reported. METHODS One hundred and forty-eight paraffin-embedded BC tissues from patients of mean age 59.27 (33-96) years and corresponding ...

2001
Vibeke Bech Thøgersen Boe Sandahl Sørensen Steen Seier Poulsen Torben Falck Ørntoft Hans Wolf Ebba Nexo

Members of the epidermal growth factor (EGF) family have been suggested as prognostic markers in patients with bladder cancer. Thus far, there has been no consensus on their usefulness. We report an analysis of six ligands and two receptors of which a subset correlate to tumor stage and survival. Biopsies from bladder cancer tumors were obtained from 73 patients followed for a median of 28 mont...

Journal: : 2022

Introduction . Cyclin-dependent kinase 4/6 inhibitors are indicated in endocrine therapy for the treatment of hormone receptorpositive, HER2-negative, advanced, or metastatic breast cancer. In recent past, abemaciclib made its debut as a combinatorial partner adjuvant hormone-dependent This article demonstrates analysis our own experience introducing into clinical practice. Aim The aim study wa...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 1997
M Bos J Mendelsohn Y M Kim J Albanell D W Fry J Baselga

PD153035 is reported to be a specific and potent inhibitor of the epidermal growth factor (EGF) receptor tyrosine kinase and, to a lesser degree, of the closely related HER2/neu receptor. We show that PD153035 inhibits EGF-dependent EGF receptor phosphorylation and suppresses the proliferation and clonogenicity of a wide panel of EGF receptor-overexpressing human cancer cell lines. EGF receptor...

Journal: :Journal of virology 2008
Laura Menotti Arianna Cerretani Hartmut Hengel Gabriella Campadelli-Fiume

A novel frontier in the treatment of tumors that are difficult to treat is oncolytic virotherapy, in which a replication-competent virus selectively infects and destroys tumor cells. Herpes simplex virus (HSV) represents a particularly attractive system. Effective retargeting to tumor-specific receptors has been achieved by insertion in gD of heterologous ligands. Previously, our laboratory gen...

Journal: :Journal of the National Cancer Institute 2015
Eduardo Pérez-Gómez Clara Andradas Sandra Blasco-Benito María M Caffarel Elena García-Taboada María Villa-Morales Estefanía Moreno Sigrid Hamann Ester Martín-Villar Juana M Flores Antonia Wenners Ibrahim Alkatout Wolfram Klapper Christoph Röcken Peter Bronsert Elmar Stickeler Annette Staebler Maret Bauer Norbert Arnold Joaquim Soriano Manuel Pérez-Martínez Diego Megías Gema Moreno-Bueno Silvia Ortega-Gutiérrez Marta Artola Henar Vázquez-Villa Miguel Quintanilla José Fernández-Piqueras Enric I Canela Peter J McCormick Manuel Guzmán Cristina Sánchez

BACKGROUND Pharmacological activation of cannabinoid receptors elicits antitumoral responses in different cancer models. However, the biological role of these receptors in tumor physio-pathology is still unknown. METHODS We analyzed CB2 cannabinoid receptor protein expression in two series of 166 and 483 breast tumor samples operated in the University Hospitals of Kiel, Tübingen, and Freiburg...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید